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ARTICLE
Colorectal cancer liver metastatic growth depends
on PAD4-driven citrullination of the extracellular
matrix
A.E. Yuzhalin1, A.N. Gordon-Weeks 2, M.L. Tognoli1, K. Jones1, B. Markelc 1, R. Konietzny3, R. Fischer 3,
A. Muth4, E. O’Neill 1, P.R. Thompson4, P.J. Venables5, B.M. Kessler 3, S.Y. Lim1,6 & R.J. Muschel1
Citrullination of proteins, a post-translational conversion of arginine residues to citrulline, is
recognized in rheumatoid arthritis, but largely undocumented in cancer. Here we show that
citrullination of the extracellular matrix by cancer cell derived peptidylarginine deiminase 4
(PAD4) is essential for the growth of liver metastases from colorectal cancer (CRC). Using
proteomics, we demonstrate that liver metastases exhibit higher levels of citrullination and
PAD4 than unaffected liver, primary CRC or adjacent colonic mucosa. Functional signiﬁcance
for citrullination in metastatic growth is evident in murine models where inhibition of
citrullination substantially reduces liver metastatic burden. Additionally, citrullination of a key
matrix component collagen type I promotes greater adhesion and decreased migration of
CRC cells along with increased expression of characteristic epithelial markers, suggesting a
role for citrullination in promoting mesenchymal-to-epithelial transition and liver metastasis.
Overall, our study reveals the potential for PAD4-dependant citrullination to drive the pro-
gression of CRC liver metastasis.
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The extracellular matrix (ECM) in cancer is characterized asdisorganized with increased production of some compo-nents (e.g., collagens) compared to normal tissue coun-
terparts1. In addition to altered composition, cancer-associated
ECM is subject to posttranslational modiﬁcations that alter the
interactions of ECM proteins with cancer and stromal cells2,3.
Certain ECM protein modiﬁcations are well described including
proteolytic cleavage, glycosylation, and crosslinking1. For exam-
ple, lysine crosslinking through oxidation increases the physical
stiffness of the ECM in primary tumors, altering cancer cell sig-
naling, enhancing epithelial-to-mesenchymal transition (EMT)
and driving tumor progression4.
Citrullination, the deimination of arginine residues to form
peptides containing the noncoding amino acid citrulline is a well-
recognized characteristic of chronic inﬂammation, as demon-
strated in autoimmunity5. ECM proteins such as collagens are
extensively citrullinated in patients with rheumatoid arthritis,
leading to the generation of neoantigens and as a result the for-
mation of autoantibodies6. In cancer, citrullination has been
mostly undocumented, yet inﬂammation is one of the hallmarks
of this disease7 and so citrullination may play a role in cancer
progression.
In inﬂammatory conditions, citrullination is catalyzed by
peptidylarginine deiminases (PADs) 2 and 48. In particular,
citrullination of transcription factors and histones serves as a
mechanism for transcriptional regulation of inﬂammatory
mediators9,10. Furthermore, PAD4-mediated citrullination of
histones also promotes chromatin decondensation which con-
tributes to neutrophil extracellular trap (NET) formation11.
Here, using high-throughput quantitative proteomics, we
reveal that the ECM in liver metastases contains a higher pro-
portion of citrullinated proteins than unaffected liver or primary
colorectal carcinomas (CRC). Additionally, the liver metastases
display higher levels of PAD4 than normal liver and primary
CRC or adjacent colonic mucosa. Effects of citrullination are
demonstrated in vitro with CRC cells grown on citrullinated
collagen type I exhibiting an epithelial phenotype compared to
those grown on unmodiﬁed collagen showing that ECM citrul-
lination may promote mesenchymal-to-epithelial transition
(MET). MET has been previously shown to be required for the
successful growth of tumors at metastatic sites12. Pharmacological
inhibition of PADs in vivo alters the balance toward increased
mesenchymal markers in liver metastases and reduces metastatic
growth. These results point to a new mechanism whereby cancer
cells modulate ECM citrullination to promote liver metastatic
progression.
Results
Composition of the matrisome from CRC liver metastases. We
ﬁrst characterized the composition of the ECM (so called
matrisome) from liver metastases. We modiﬁed the method of
Naba et al.13 to isolate ECM from murine experimental liver
metastases by tissue decellularization followed by removal of
contaminating cellular components through subcellular fractio-
nation, and enzymatic depletion of nucleic acids and oligo-
saccharides (Supplementary Fig. 1A). The decellularized liver
scaffolds retained a morphology consistent with ECM and con-
tained characteristic ECM proteins including collagens, Fibro-
nectin, and laminins (Supplementary Fig. 1B). The increased
proportion of high molecular weight proteins in the preparations
was consistent with enrichment of ECM proteins, as the ECM is
composed of proteins of higher molecular weight than the
intracellular compartment (Supplementary Fig. 1C).
This method was used to prepare ECM from human CRC liver
metastases and adjacent uninvolved liver directly after surgical
resection for mass-spectrometry proteomic analysis (Supplemen-
tary Fig. 2A–C). Of 1097 proteins identiﬁed by qualitative
analysis (Supplementary Data 1A), 158 were recognized as ECM
components based on the Human Matrisome dataset13 (Supple-
mentary Fig. 3A, Supplementary Data 1B). Proteomics results
exhibited low inter-sample variability in protein content and
considerable overlap of the matrisomal proteins (Supplementary
Fig. 3B, C). Matrisomal proteins found in hepatic metastases are
listed in Supplementary Fig. 3D and Supplementary Data 1C.
Interestingly, many of the identiﬁed proteins were initially not
categorized as ECM-derived using the Human Matrisome dataset,
but reclassiﬁcation with the Panther system14 identiﬁed the
majority as ECM or components of extracellular vesicles (EVs)
(Supplementary Fig. 3E, Supplementary Data 1D). This suggests
that many of these non-matrisomal proteins could not be cellular
contaminants, but instead were the result of retention of EV
contents by the ECM.
We then applied quantitative label-free analysis to the
proteomic data (Supplementary Data 2A, B). Using principal
component analysis and clustering on the quantitative data
(Fig. 1a, b) we identiﬁed 287 proteins with statistically signiﬁcant
differential abundance between the normal non-cancerous liver
and metastases (two-way ANOVA, FDR-adjusted P < 0.05)
(Fig. 1c), of which 69 with fold change of >3 were consistently
up- or downregulated within the ECM (Fig. 1d, Supplementary
Data 2 C, D). Many of the upregulated proteins have previously
been linked to metastatic progression, including Versican,
TIMP1, LTBP1-3, DDR1, and S100A1015–19.
To conﬁrm the proteomics, the expression of six selected
proteins was assessed using immunoblotting and immunostaining
on an independent set of resected hepatic metastases from
additional CRC patients. Differential expression similar to the
proteomic results was conﬁrmed for all the proteins tested;
versican, tenascin, S100A11, and COL5A1 were overexpressed,
while matrix metalloproteinase-23 and mimecan were down-
regulated in the liver metastases compared to adjacent liver
(Supplementary Fig. 4A–D).
ECM proteins are highly citrullinated in liver metastases. We
next compared the citrullinome (i.e., the ensemble of citrullinated
proteins) in liver metastases and adjacent normal liver using a
PEAKS® software pipeline20 to search for citrullinated residues in
the data described above (Fig. 2a, Supplementary Fig. 5A). ECM
from CRC liver metastases contained higher numbers of citrul-
linated peptides than adjacent normal liver (Fig. 2b, Supple-
mentary Data 3A, B). Most of the citrullinated peptides were from
proteins classiﬁed as matrisomal. Surprisingly, some proteins
frequently citrullinated in rheumatoid arthritis22 (e.g., vimentin,
ﬁbrin, and tenascin) were mainly unmodiﬁed in CRC liver
metastases. On the other hand, proteins previously not reported
to be citrullinated, for example, ﬁbrillin-1 and emilin-1, were
highly citrullinated in metastatic lesions (Supplementary Fig. 5B).
To extend our results from human samples, we analyzed the
ECM-associated citrullinome from murine experimental liver
metastases generated through the intrasplenic injection of HT29
and LoVo cancer cells. There was considerable overlap with the
data from human liver metastases, with ﬁbrillin-1, emilin-1, and
collagens being the most abundantly citrullinated proteins in liver
metastases (Fig. 2c, d).
We then assessed the extent of overall protein citrullination in
a different set of human liver metastases using two different
methods, an ELISA and immunoblotting for 2,3-butanedione
monoxime-modiﬁed citrullinated residues, both of which recog-
nize citrullinated proteins, but not free citrulline22. These
experiments conﬁrmed the presence of increased amounts of
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citrullinated proteins in liver metastases compared to adjacent
liver, primary CRC, or uninvolved colon samples (Fig. 2e, f,
Supplementary Fig. 6A, B). The level of citrullinated peptides was
also increased in ECM from CRC liver metastases compared to
adjacent non-cancerous liver, primary CRCs, and uninvolved
colon (Fig. 2g). Collectively, these data demonstrate that
citrullinated ECM proteins are characteristic of liver metastases,
but not primary colon tumors suggesting that citrullination may
be an important component of the metastatic process.
PAD4 is deposited in the ECM of hepatic metastases. We then
considered peptidylarginine deiminase 4 (PAD4) as a candidate
to account for the increased citrullination of proteins in the liver
metastatic ECM, because it was 11 times more abundant in the
metastatic ECM than the uninvolved liver based on proteomics
data (Fig. 1d). None of the other PADs were detected in the ECM
by proteomics. PAD4 levels in lysates of human liver metastases
showed a trend to be increased compared to the adjacent liver
based on ELISA measurements and were signiﬁcantly increased
based on immunoblotting (Fig. 3a, b, Supplementary Fig. 6A, B).
PAD4 exists as a 74 kDa monomer, which is less enzymatically
active than dimeric PAD423. The dimeric form was generally
more abundant in our samples (Supplementary Fig. 6A, B). In
addition, more minor intermediate bands which could include
degradation products and some non-speciﬁc reactivity were seen
(Supplementary Fig. 6A, B). These bands were enhanced after
overexpression. Further the antibody shows speciﬁcity in that it
reacts with recombinant PAD4 (Supplementary Fig. 6D). The
concentration of Ca+2 which regulates dimerization is likely to
vary depending on the nature of the sample23. We did not ﬁnd
increased levels of PAD4 in tissue lysates from human primary
CRC or in adjacent uninvolved colon samples, suggesting that
PAD4 upregulation is speciﬁc to liver metastases (Fig. 3a, b,
Supplementary Fig. 6B).
To identify the cell types that produce PAD4 in the hepatic
metastatic environment, we sorted cells from murine experi-
mental liver metastases generated from three different human
CRC cell lines into four groups: cancer cells expressing GFP,
granulocytes (CD11b+Ly6Ghi), other myeloid cells (CD11b
+Ly6Glo) and the remaining stromal cells (GFP−, CD11b−,
Ly6G−) (Supplementary Fig. 6C). Strikingly, for each tumor type,
cancer cells expressed considerably higher amounts of PAD4
when compared with host cells (Fig. 3c). Further, PAD4 protein
was produced by multiple cancer cell lines, including those
isolated from metastatic sources (LoVo, SW620) and also found
in experimental liver metastases (Supplementary Fig. 6D). To
conﬁrm that neutrophils do not produce the majority of PAD4 in
metastatic microenvironment, we depleted neutrophils using Ly6-
G antibody24 (Supplementary Fig. 7A). Liver metastases from
mice depleted of neutrophils had similar levels of PAD4 and
protein citrullination as controls (Supplementary Fig. 7B, C).
Thus, CRC cells often express PAD4 and appear to be the
predominant source of PAD4 in the metastatic microenviron-
ment in murine models.
We next investigated the mechanism through which cellular
PAD4 is delivered to the ECM. PAD4 concentration increased
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with time in CRC cell conditioned media, and extracellular
molecule was present in its more active dimer form (Fig. 3d, e).
Although this data demonstrates secretion of PAD4 by CRC cells,
PAD4 lacks a deﬁned secretory peptide raising the question of
mechanisms for its release. We asked whether PAD4 was present
in EVs, which would be consistent with the extensive deposition
of proteins associated with EVs in the ECM of human liver
metastases (Supplementary Fig. 3E). In keeping with deposition
of PAD4 through vesicle release, EVs isolated from cancer cell
conditioned media (Fig. 3f) contained PAD4 as well as many
characteristic EV markers including caveolin-1 and β-catenin and
lacked markers of ER and of Golgi apparatus (Fig. 3g,
Supplementary Fig. 8A). PAD4 was enriched in EVs in the
conditioned medium (Supplementary Fig. 8B). Exposure of HT29
to the sphingomyelinase inhibitor GW4869, a potent inhibitor of
EV release25, led to more than a twofold reduction in EV number
(Fig. 3h), and a corresponding decrease in PAD4 levels in the
conditioned media, without altering intracellular PAD4 levels
(Fig. 3i). HT29 but not HCT116 and LoVo, was unaffected by
GW4869 in a WST-1 assay of cell proliferation and viability
(Supplementary Fig. 8C). Hence EVs were only analyzed from
HT29. Finally, immunohistochemistry of human CRC liver
metastases revealed extracellular PAD4 localization. The extra-
cellular PAD4 colocalized to collagens type I and IV providing
additional evidence for the presence of PAD4 in the tumor ECM
(Fig. 3j and Supplementary Fig. 8D). Additional PAD4 was
associated with cellular areas.
Taken together, these data testify to the deposition of PAD4 in
the ECM of hepatic metastases. EV-driven secretion of proteins
without secretory peptides such as IL−1β has previously been
documented26, and while these data do not exclude alternative
modes of secretion, they suggest that PAD4 can be released in EVs.
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Citrullinated collagen alters CRC adhesion, motility, and EMT.
To investigate the effect of ECM citrullination on cancer cell
phenotypes, we plated CRC cells on citrullinated and non-
citrullinated collagen type I. We chose collagen type I for these
studies because it was one of the most highly expressed compo-
nent of the liver metastatic ECM and also was extensively
citrullinated (Supplementary Data 2B, Supplementary Fig. 5B).
To generate citrullinated collagen, we incubated recombinant
collagen type I with activated recombinant PAD4. As a control we
added the PAD inhibitor BB-Cl-amidine27 to inhibit citrullina-
tion (Fig. 4a, Supplementary Fig. 9A). Citrullinated collagen type
I did not alter viability or proliferation of cultured CRC cells
(Supplementary Fig. 9B, C). Adhesion of CRC cells was sig-
niﬁcantly greater to citrullinated collagen type I than to the non-
citrullinated controls (Fig. 4b, Supplementary Fig. 10). Cell
motility, measured by median velocity and track length was also
signiﬁcantly decreased in colon cancer cells plated on citrullinated
collagen type I compared to controls, albeit by only ∼20–30%
(Fig. 4c, d). These data implicate citrullination of the ECM in the
promotion of cancer cell adhesion and inhibition of their motility,
characteristic features of an epithelial cell phenotype.
We then examined the effect of cell adhesion to citrullinated
collagen type I on downstream signaling. Focal adhesion kinase
(FAK) is an integrin-dependent regulator of cell motility linked to
EMT28. Phosphorylation of FAK and of its downstream targets,
ERK and JNK, was decreased in CRC cells seeded onto
citrullinated collagen type I in comparison to control, consistent
with the increased attachment and decreased motility observed
(Fig. 4e). Moreover, when plated on citrullinated collagen type I,
the MC38 and LoVo CRC cells exhibited increased expression of
epithelial markers (Fig. 4f, Supplementary Fig. 11). In particular,
RNA expression of mesenchymal markers N-cadherin (CDH2)
and Snail1 and 3 (SNAI1 and 3) were reduced in MC38 cells
plated onto citrullinated collagen, while expression levels of
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E-cadherin (CDH1) and other epithelial markers were increased.
Reciprocal changes in N- and E-cadherin were conﬁrmed at the
protein level by immunoblotting (Fig. 4g). Thus, adhesion to
citrullinated collagen type I promoted alterations in EMT
markers in CRC cell lines.
PAD inhibition abates liver metastatic growth and alters EMT.
To determine whether analogous events occur in vivo, we treated
mice in an experimental liver metastasis experiment with the
PAD inhibitor BB-Cl-amidine27. This resulted in a consistent
decrease in the amount of citrullinated proteins in the liver
colonies of the human CRC cells, although there was substantial
variation between individual mice (Fig. 5a, b, c). Because the
commercial antibody to 2,3-butanedione monoxime-modiﬁed
citrulline is human-speciﬁc, we used immunohistochemistry for
citrullinated Histone H3 to demonstrate a trend to reduced
citrullination in the MC38 murine experimental metastasis model
(Fig. 5d, e). The decrease in citrullinated proteins in the liver
colonies correlated with a three- to fourfold reduction in meta-
static burden (Fig. 5f–i). Metastases from untreated mice with
more extensive citrullination exhibited strong expression of the
epithelial markers E-cadherin, cytokeratin 7 and tight junction
protein-1 and decreased expression of the mesenchymal markers
ZEB1 and N-cadherin (Fig. 6a, b). In contrast, BB-Cl-amidine-
treated tumors exhibited the reverse with decreased expression of
epithelial markers and increased expression of mesenchymal
markers. Thus, reduction of PAD activity and decreased citrul-
lination enhanced expression of mesenchymal markers and
concurrently impaired metastatic growth.
Administration of BB-Cl-amidine had no effect on growth of
HCT116 subcutaneous xenografts but resulted in an approxi-
mately two- to threefold decrease in LoVo and MC38 xenograft
volume (Fig. 6c). The markers of epithelial-mesenchymal
plasticity of these subcutaneous tumors were not altered upon
BB-Cl-amidine treatment (Fig. 6d), suggesting that PAD/
citrullination did not have a substantial effect on tumors in a
non-metastatic subcutaneous location.
We then asked whether downregulation of the PAD4 gene in
CRC cells had analogous effects to pharmacological inhibition.
PAD4 levels were reduced by introduction of the shRNA in HT29
and HCT116 cells (Fig. 7a) and resulted in decreased intracellular
and secreted protein citrullination (Fig. 7b) in comparison with
cells transfected with control lentivirus. In tissue culture
expression of the EMT markers N- and E-cadherin was
unchanged suggesting that intracellular PAD4 and intracellular
citrullination have minimal effects on epithelial-mesenchymal
plasticity in these cells (Supplementary Fig. 12A). This is in
striking contrast to the shift in EMT markers observed after
plating the cells with downregulated PAD4 on citrullinated
collagen type I suggesting that engagement with citrullinated
ECM rather than intracellular PAD4 drove the changes in EMT
characteristics. Of note, overexpression of PAD4 following
transduction by an expression vector did not change the amounts
of N- or E-cadherin or Slug (Supplementary Fig. 12B).
Subcutaneous tumors from the PAD4-depleted HT29 and
HCT116 cells had diminished PAD4 levels. Citrullination of
proteins in cell lysates and decellularized and enriched matrices
from subcutaneous xenografts was also decreased (Fig. 7c). HT29
cells had reduced growth in vitro, while HCT116 had a slight yet
signiﬁcantly reduced saturation density. Both showed decreased
growth as subcutaneous tumors (Fig. 7d, e). We injected wild-
type and PAD4 knockdown cells intrasplenically to assess their
growth as liver colonies. Strikingly, PAD4-deﬁcient cells failed to
form experimental liver metastases, suggesting the importance of
this protein in the formation of liver colonies in vivo (Fig. 7f–h).
We next performed a spontaneous metastasis assay using
orthotopic injection of HCT116 cancer cells into the cecal wall of
mice (Fig. 8a). The cells with wild-type or PAD4 gene knockdown
led to bowel tumors with similar weights in contrast to the
decreased growth at the subcutaneous site (Fig. 8b). The number
of visible liver macrometastases (1–3 mm), however, was
considerably decreased in the mice with PAD4-deﬁcient cecal
tumors (Fig. 8c). To evaluate the number of micrometastases, we
sectioned the livers and counted the number of lesions as assessed
by GFP positivity or histological evaluation (Fig. 8d). Both
methods conﬁrmed the marked reduction of micrometastases in
the PAD4 gene knockdown group compared to controls (Fig. 8e,
f). Unexpectedly, the expression of PAD4 was higher in
metastases from mice injected with PAD4-deﬁcient cells (Fig. 8g),
even though PAD4 levels were lower in the primary lesions of the
PAD4 knockdown group (Fig. 8h). This data implies that the few
established metastases that developed may have arisen from cells
which had escaped PAD4 knockdown. This ﬁnding is consistent
with a metastasis-speciﬁc requirement for PAD4. Taken together,
these data suggest that reduction of in vivo activity of PAD4 in
liver metastatic CRC cells diminishes growth of liver colonies.
Discussion
ECM and its modiﬁcations orchestrate many facets of tumor
biology including tumorigenesis, invasion and metastasis. The
liver is the most common site for distant metastasis in CRC and
poor survival for this disease is often attributable to metastasis29.
Here we identify citrullination generated by PAD4 derived from
tumor cells as a driver of human CRC liver metastases. Our
experiments showing that citrullination of the ECM and expres-
sion of PAD4 facilitate human liver CRC metastasis may create
opportunities for development of biomarkers and for therapeutic
targeting.
We found PAD4 at higher levels in human CRC liver metas-
tases than in primary CRC, or adjacent colon or liver. Consistent
with the enzymatic activity of PAD4, citrullinated residues were
present at higher levels in both total lysates and in the ECM of
liver metastatic tissues than in primary CRC, liver, or colon. Our
evidence suggests that extracellular PAD4, possibly through
citrullination of collagen type I and other ECM proteins, alters
the characteristics of CRC cells. Downregulation of PAD4 in
tissue culture, a situation in which ECM is sparse did not alter
EMT characteristics. However, plating cells on citrullinated col-
lagen altered their EMT features regardless of intracellular PAD4.
In experimental liver metastasis models, downregulation or
pharmacological inhibition of PAD4 reduced citrullination and
liver metastatic growth. Taken together, these experiments sug-
gest that the citrullination of ECM molecules requiring extra-
cellular PAD4 could be an important event in altering CRC cell
signaling during metastatic growth. Unlike the CRC cells used
here, downregulation of PAD4 in breast cancer cells30 resulted in
increased EMT markers Smad4 and p-Smad2, while over-
expression of PAD4 in lung cancer cells31 inhibited EMT through
suppression of Elk1. Thus, signaling to reduce EMT marker
expression may be mediated both intra- and extracellularly,
reinforcing the possibility that PAD4 and citrullination might be
a therapeutic target in liver metastases.
Although our work has focused upon PAD4, we recognize that
citrullination can be catalyzed by other homologous PAD enzymes,
including PADs 1–3 and 6. PAD2 and 4 are most broadly expressed
in adults8 and only PAD4 has a canonical nuclear localization
sequence32. Of the PADs, however, PAD4 has been more often
suggested to have the potential for involvement in cancer as it is
overexpressed in tissues from many different malignancies includ-
ing CRC33, while PAD2 expression is downregulated in CRC
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compared to adjacent colonic mucosa34. The release of PAD4 from
the cancer cells is clearly complex. Part of this release may be
through EVs. This could be analogous to the release of IL-1β or
other secreted molecules which also lack a secretory peptide and can
be secreted in EVs, which then through unknown mechanism
release their contents into the extracellular space26,35,36. The release
through EVs is supported by our ﬁnding of enrichment of vesicle
contents in general within the cancer ECM.
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Other molecules we identiﬁed in the ECM of metastatic liver
also have the capacity to affect EMT. Versican, which was con-
siderably overexpressed in liver metastasis ECM, has been
reported to induce MET37. TGF-β signaling has been recognized
as critical to CRC liver metastasis38 and we found upregulation of
the TGF-β binding proteins LTBP1-3, TSP1, and TSP2, some of
which contribute to TGF-β activation39,40. TGF-β has been linked
to tumor suppression through EMT42, and citrullination of TGF-
β altered its activity42. The complex balance between these signals
and the function of epithelial-mesenchymal plasticity in cancer is
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still not completely understood. Genetic manipulation of EMT in
murine cancer models leads to increased invasion and migration
by metastatic cells43 while more recent work implicates EMT in
promotion of tumor-initiating cells and resistance to
chemotherapy44,45. After dissemination, MET has been suggested
to be necessary to initiate metastatic colony formation46–48.
Further, MET has been documented in human CRC liver
metastases as demonstrated by Hur et al.49, showing markers for
MET in liver metastases compared to their matched primary
lesions. This is consistent with our data and the hypothesis that
cancer cell secretion of PAD4 leads to MET due to modiﬁcation
of the metastatic liver ECM by citrullination with the result of
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Fig. 8 Genetic downregulation of PAD4 in HCT116 cells diminishes spontaneous hepatic metastases in vivo. a Experimental pipeline. b Weight of excised
primary cecal tumors (n= 8 biological replicates per group). c Number of visible macrometastases (n= 10 biological replicates per group). Other organs
including lungs showed no evidence of metastasis. d Representative image of a GFP+ metastatic lesion counterstained with DAPI (left and middle) and the
corresponding H&E image (right). Scale bar= 100 μm. e Numbers of GFP+ micrometastatic lesions observed (n= 5 biological replicates per group). f Area
of micrometastases evaluated by H&E (n= 5 biological replicates per group). g Relative (to HPRT) mRNA levels of PAD4 in visible macrometastases (n= 6
and 4 for CTL and shPAD4 groups, respectively). h Relative (to HPRT) mRNA levels of PAD4 in primary cecal lesions (n= 7 and 6 for CTL and shPAD4
groups, respectively). Throughout, error bars indicate s.e.m. center values indicate mean (*P < 0.05, **P < 0.01, n.s.= non-signiﬁcant, Mann–Whitney U
test). CTL control, shPAD4 PAD4 knockdown, H&E hematoxylin and eosin
Fig. 7 Genetic downregulation of PAD4 diminishes proliferation and subcutaneous tumor growth of CRC cells, and reduces experimental metastasis in vivo.
a Immunoblotting for PAD4 in HT29 and HCT116 cells transfected with lentivirus harboring scrambled shRNA (CTL) or shPAD4 (shPAD4 #1 and #2).
GAPDH was used as a loading control. b Immunoblotting for citrullinated proteins in conditioned media and cell lysates from control and PAD4-deﬁcient
HT29 and HCT116 cells. GAPDH was used as a loading control. c Immunoblotting analysis for PAD4 and citrullinated proteins in tissue lysates and isolated
ECM from control (CTL) and PAD4 knockdown (shPAD#1) subcutaneous xenografts. GAPDH and COL5A1 were used as loading controls for tissue lysates
and isolated ECM, respectively. dWST-1 proliferation and viability assay performed in cultured wild-type and PAD4-deﬁcient HT29 and HCT116 cells (n= 5
technical replicates per group). e Tumor growth curves of mice injected subcutaneously with control and PAD4-knockdown HT29 and HCT116 cells (n= 7,
4, and 5 biological replicates for HT29 and 9, 5, and 5, for HCT116, respectively). Repeated twice. f Representative images of livers from mice injected
intrasplenically with control (n= 8 biological replicates) or PAD4-deﬁcient HT29 and HCT116 cells (n= 6 and 6 biological replicates for shPAD4 #1 and
#2) 35 days postinjection. Metastatic nodules are outlined in blue. g Liver weights from the experiment in (f). h Measurement of the area of metastatic
deposits in HT29 livers from the experiment in (f). For g, error bars indicate s.e.m. center values indicate mean (**P < 0.01, Kruskal–Wallis test with Dunn’s
multiple comparison post-test). For d and e, error bars indicate s.e.m. center values indicate mean (***P < 0.001, two-way ANOVA). Ms mouse, CTL
control, shPAD4 PAD4 knockdown, ECM extracellular matrix
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facilitating metastatic growth. This hypothesis points to cancer
cell plasticity being enforced by an extracellular signal, that of
citrullination of ECM components. This novel mechanism could
be exploited by cancer cells to secure their growth at distant sites,
and interruption of this signaling could generate an unfavorable
microenvironment for cancer cell growth. Therefore, PAD4 and
citrullination might be a possible target in therapy of liver
metastases.
Extensive protein crosslinking and insolubility makes separa-
tion of the ECM from cellular contents difﬁcult and proteomic
analysis of the tumor ECM is therefore challenging. Here for the
ﬁrst time we demonstrate a method for high-throughput quan-
titative proteomics of tumor ECM, in which efﬁcacy was inde-
pendently validated by other methods and could be used to detect
protein modiﬁcation. These methods should be widely applicable
to future studies of cancer ECM.
Finally, our group further demonstrated the signiﬁcance of
cancer matrisome in a recent bioinformatics study by implicating
a combination of nine core ECM proteins in predicting cancer
survival across large cohorts of cancer patients50.
Methods
Human samples. Human primary CRC and uninvolved colon from the same
resection specimens as well as hepatic CRC metastasis tissue and surrounding
unaffected liver tissue from resection specimens were obtained from patients from
the Oxford Radcliffe Biobank following institutional review and granting of ethical
approval (ethics number 09/H0606/5). Informed consent was obtained from all
subjects involved.
Cell lines. The following cell lines were used in the study: SW480, SW620, DLD-1,
HT29, HCT116, LoVo (all human colon cancer), MC38 (mouse colon cancer),
OE33 (human esophageal cancer), and HeLa (human cervical cancer). All the cell
lines were purchased from American Type Culture Collection (ATCC), except for
MC38 and OE33 which were purchased from Kerafast and Sigma, respectively.
Early passage SW480, SW620, DLD-1, HT29, HCT116, and OE33 cell lines were
cultured in Roswell Park Memorial Institute (RPMI-1640) media (R8758; Sigma).
Early passage MC38, and HeLa cell lines were cultured in Dulbecco’s Modiﬁed
Eagle Medium (DMEM) media (D2429; Sigma). All media were supplemented with
10% fetal bovine serum (FBS, 16000-044; Thermo Fisher), and 100 IU/ml peni-
cillin/streptomycin (15140-122; Thermo Fisher). All cells were cultured under
sterile conditions and maintained in a 37 °C incubator with 5% CO2, regularly
tested for mycoplasma and genetically authenticated by CRUK Cancer Centre
Genomics Facility, Leeds, UK. Cell lines were passaged upon reaching ∼80–90%
conﬂuency and their morphology was regularly checked to ensure the absence of
cross contamination between cell lines or mycoplasma contamination. To deter-
mine cell number, the automated cell counter NucleoCounter NC-100 (Chemo-
metec) or manual hemocytometers were used.
Cell transfection. For the generation of cell lines stably expressing green ﬂuor-
escent protein (GFP), cells were infected with a lentivirus containing a gene
encoding GFP driven by CMV promoter (CLS-PCG-8; Qiagen). For transfection,
5 × 103 cancer cells were spun at 3000 r.p.m. After that, cells were kept for 30 min
at 4 °C in media supplemented with 8 µg/ml polybrene (H9268; Sigma-Aldrich)
and lentivirus particles at various multiplicities of infection (2–8). After spinocu-
lation, cells were plated in 12-well plates and cultured in a 37 °C incubator with 5%
CO2. Two days post transfection, lentivirus-containing media was replaced with
fresh media containing puromycin (P8833; Sigma-Aldrich) at a pre-determined
concentration (depends on a cell line). Cells were FACS-sorted for GFP after
reaching conﬂuency. Following sorting, cells were cultured in puromycin-
containing media at a pre-determined concentration. For PAD4 knockdown,
lentiviral particles were purchased from Origene (TL310630) and transfection was
performed in the same way as described above.
For PAD4 overexpression, the pCHD-CMV-MCS-EF1-Hygro vector (System
Biosciences) was used with the ﬁreﬂy luciferase gene cloned in the ﬁrst MCS and
human PAD4 cloned in the second MCS. Control cells were transfected with
lentivirus harboring a scramble shRNA. Cell transfection using this vector was
performed in accordance with manufacturer’s instructions.
BB-Cl-amidine. The BB-Cl-amidine compound was synthesized and provided by
Paul R Thompson, at the Department of Biochemistry and Molecular Pharma-
cology, University of Massachusetts Medical School, USA. Lyophilized BB-Cl-
amidine was diluted in 100% DMSO to a concentration of 40 mg/ml, aliquot and
stored at −20 °C before use. For in vivo administration, BB-Cl-amidine was diluted
in PBS to reach the desired concentration of 7.5 mg/kg.
Animal experiments. All animal experiments were performed according to the
UK Animal Scientiﬁc Procedures Act 1986, institutional guidelines of the Uni-
versity of Oxford, as well as published guidelines for the welfare and use of animals
in cancer research51. All experiments involving mice were conducted within the
limits of the Project License issued by the Home Ofﬁce, UK (PPL numbers 30/2841
and 30/3413). Animals were housed in speciﬁc pathogen-free facilities with con-
trolled conditions of temperature (24 ± 1 °C) and humidity (55 ± 10%), and had
access to water and food (rodent pellets) ad libitum. Throughout the whole time of
experiment 12 h light/dark cycles were carefully maintained. Female severe com-
bined immunodeﬁciency (SCID) mice aged 6–8 weeks were purchased from
ENVIGO (Bicester, UK). Female C57BL/6 mice aged 6–8 weeks were purchased
from Charles River Laboratories (Kent, UK). Prior to tissue harvest, adult C57Bl/6
mice were humanely culled by means of intraperitoneal injection of 200 µl pen-
tobarbitone, and organs were dissected thereafter. For hepatic metastases model,
mice were ﬁrst anesthetized using vaporized isoﬂurane. After that, the upper lateral
abdominal wall was incised and 1 × 106 HT29, HCT116, or LoVo cells, or 5 × 105
MC38 cells in 100 µl PBS were injected into parenchyma of the spleen. The spleen
was removed by electrocautery 1 min post-injection to prevent primary tumor
growth in the splenic bed. The wound was then closed using non-soluble sutures
and autoclips. SCID mice injected with HT29, HCT116, or LoVo cells were
sacriﬁced 35 ± 2 days following surgery. C57BL/6 mice injected with MC38 cells
were sacriﬁced 13 ± 2 days following surgery. For intracecal injection, mice were
ﬁrst anesthetized using vaporized isoﬂurane. After that, a transverse upper
abdominal wall incision was made, the cecum was exteriorized, and 1 × 106 wild-
type or shPAD4 HCT116 cells in 50 µl PBS were slowly injected between the
mucosa and the muscularis layers of the cecal wall. After injection, the cecum was
returned to the abdominal cavity and the wound was closed with surgical sutures
and autoclips. For in vivo PAD4 inhibition experiments, randomized SCID or
C57BL/6 mice were administered with 7.5 mg/kg BB-Cl-amidine or 3–5% DMSO
in 100 µl PBS intraperitoneally every 48 h starting from the day 1 after the
intrasplenic or subcutaneous injection. For neutrophil depletion experiments, 12.5
μg/kg of anti-Ly6G (clone 1A8; BD Biosciences, Oxford, UK) was injected
intrasplenically every 24 h. An isotype control antibody immunoglobulin [Ig] G2a
was injected as a control. Mice were randomized before the start of the treatment,
using a random number generator. No animals were excluded.
Liver decellularization optimization. Livers were obtained from mice after
sacriﬁce. For whole liver decellularization, different detergents were tested. Dis-
sected mouse livers were washed in phosphate-buffered saline (PBS) and placed in
Petri dishes with 4 different solutions: (1) 1% sodium dodecyl sulfate (SDS) and
0.01% ammonium hydroxide (NH4OH) in ddH2O, (2) 2% TritonX-100 and 0.1%
NH4OH in ddH2O, (3) 1% TritonX-100 diluted in PBS, and (4) 1% SDS diluted in
PBS. The dishes were placed on a rotary shaker for 72 h; solutions were changed
every 6 h during the day, and left at −4 °C overnight. Decellularization was assessed
visually every 12 h, and images were taken using a digital camera. As a result, 1%
SDS and 0.01% NH4OH in ddH2O was considered the best buffer for
decellularization.
ECM preparation. Human hepatic metastasis tissues and adjacent unaffected liver
tissues were decellularized in a buffer containing 0.1% SDS and 0.01% NH4OH in
ddH2O for 72 h, cut into 100 mg pieces (wet weight), aliquot into 200 µl of ice cold
buffer C (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) pH 7.9,
MgCl2, KCl, EDTA, sucrose, glycerol, sodium orthovanadate, protease inhibitor
cocktail) of the CNMCS Compartmental Protein Extraction Kit (K3013010; Bio-
Chain Institute), ﬂash frozen in liquid nitrogen and kept at −20 °C until
enrichment.
ECM enrichment. Frozen ECM samples were thawed, then homogenized using the
Tissue-Tearor tissue homogenizer (BioSpec Products) at speed 4 or 5 for 25 s on
ice. Homogenization was repeated two to three times; the probe was cleaned with
100% ethanol and PBS between samples. The samples were further processed on
the high intensity VCX-130 ultrasonic processor (Sonics&Materials) at 4 °C with
the following settings: 100% amplitude, 2 s on/2 s off, 20 s in total (including offs).
The samples were then deglycosylated with 3000–4000 units of PNGase F (P0704;
New England BioLabs) and contaminating nucleic acids were removed by adding
1 μl Benzonase® nuclease (E1014; Sigma) for 1 h at 4 °C. The samples were then
spun down at 18,000 × g for 20 min. The supernatant was discarded, and the pellet
was washed in 400 μl of ice cold buffer W (HEPES (pH7.9), MgCl2, KCl, EDTA,
sucrose, glycerol, and sodium orthovanadate, hereinafter, concentration of each
component is not speciﬁed by a supplier) of the CNMCS Compartmental Protein
Extraction Kit at 4 ˚C for 5 min. The washed protein extract was spun at 18,000 × g
for 20 min. The supernatant was discarded, and the pellet was resuspended in
150 μl of ice cold buffer N (HEPES (pH7.9), MgCl2, NaCl, EDTA, glycerol, sodium
orthovanadate) and incubated at 4 °C for 20 min to solubilize nuclear proteins.
Protein extract was spun at 18,000 × g for 20 min. The supernatant was discarded,
and the pellet was resuspended in 150 μl of ice cold buffer M (HEPES (pH7.9),
MgCl2, KCl, EDTA, sucrose, glycerol, sodium deoxycholate, NP-40, sodium
orthovanadate) for membrane proteins solubilization. The extracts were then spun
down at 18,000 × g for 20 min, and the supernatant was discarded. The remaining
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pellet was resuspended in 150 μl of pre-warmed buffer CS (Pipes (pH6.8), MgCl2,
NaCl, EDTA, sucrose, SDS, and sodium orthovanadate) and incubated at RT for
20 min to solubilize cytoskeletal proteins. Protein extract was spun at 18,000 × g for
20 min. Finally, the supernatant was withdrawn, and the pellet was resuspended in
150 μl of buffer C, incubated at 4 °C for 5 min and then spun for 20 min at
15,000 × g at 4 °C. The remaining insoluble pellet consisting of ECM proteins was
then ﬂash frozen in liquid nitrogen and kept at −20 °C.
Biochemical processing of ECM-enriched proteins. ECM-enriched samples were
solubilized in 8M urea (9U5378; Sigma), 100 mM ammonium bicarbonate (09830;
Sigma), 10 mM dithiothreitol (DTT, 43817; Sigma), pH 7.8, and incubated at 37 °C
for 30 min. Alkylating agent iodoacetamide (I1149; Sigma) was added to a ﬁnal
concentration of 25 mM and the samples were incubated for 30 min at RT. Protein
samples were then precipitated via the routine methanol/chloroform method,
followed by resuspension in 50 μl 8M urea and vortexing. Finally, the urea con-
centration was reduced to a ﬁnal concentration of <1M by diluting the reaction
mixture with ddH2O. At this point, to determine the concentration of protein for
the proteomics, we used the DC™ (detergent compatible) protein assay according to
instructions (5000111; Bio-Rad). ECM-enriched pellets were digested overnight
using trypsin (V5111; Promega), at a ratio of 1:50 enzyme:substrate. The samples
were constantly vortexed on a shaker at 37 °C. A second aliquot of trypsin was
added at a ratio of 1:100 enzyme:substrate, and samples were incubated for addi-
tional 4–6 h at 37 °C with shaking.
Mass spectrometry. The samples were processed with nano–liquid chromato-
graphy tandem mass spectrometry (nano–LC-MS/MS), utilizing the Acquity LC
instrument (C18 column with a 75 µm × 250 mm, 1.7 µm particle size; Nanoacquity
Waters) coupled to a Thermo LTQ Orbitrap Elite mass spectrometer (resolution of
120,000 at 400 m/z, Top 20, collision-induced dissociation), using a gradient of
1–35% acetonitrile for 60 min at a ﬂow rate of 250 nl/min. Peak lists containing
MS/MS spectra were generated using MSConvert (Proteome Wizard). After that,
these lists were searched using Mascot version 2.3 (http://www.matrixscience.com),
against the Swiss-Prot protein database containing mouse (16,642 entries as of
September 2012) or human (20,306 entries as of June 2014) sequences, with tryptic
restriction and mass deviations of 10 parts per million/0.5 daltons in the respective
MS modes. Oxidation of methionine, deamidation of asparagine and glutamine,
and other known collagen and proteoglycan modiﬁcations were used as variable
modiﬁcations. Peptide false discovery rate was adjusted to 1%. For label-free
quantiﬁcation of differentially expressed proteins, normalized abundance of each
protein was determined by measuring the peak area intensity utilizing the Pro-
genesis QI software (Nonlinear Dynamics). Brieﬂy, protein abundance was cal-
culated from the sum of all unique peptide ion abundances for a speciﬁc protein on
each run. Normalization of abundance was performed to allow comparisons across
different sample runs by the software. Proteins identiﬁed by more than one peptide
were retained. The normalized peptide intensities for each sample were used to
calculate fold change ratios for proteins between sample groups.
Protein categorization. ECM proteins were split into ﬁve major groups: pro-
teoglycans, glycoproteins, collagens, ECM regulators, ECM-afﬁliated proteins and
secreted factors according to the categorization proposed by Naba et al. (2012).
Gene Ontology term enrichment analysis for cellular localization was performed
using the PANTHER bioinformatics resource (http://pantherdb.org/).
LC-MS/MS detection of citrulline residues. LC-MS/MS data were analyzed in
PEAKS® software (V.6; Bioinformatics Solutions, Waterloo, ON, Canada) using the
posttranslational modiﬁcation search option at mass tolerances of 10 ppm for MS1
and 0.5 Da for MS2 at 1% false discovery rate (FDR). Citrullinated peptides were
manually inspected when the citrullinated residue produced a missed cleavage. To
exclude false positive assignment of citrullination, we conﬁrmed correct precursor
and fragment mass assignments (monoisotopic mass instead of 13C isotopic peak)
and also excluded deamidation, which exhibits the same mass shift.
Antibodies. The list of antibodies used in the study is provided in the Supple-
mentary Data 4.
In vitro citrullination studies. For all experiments involved in vitro citrullination,
recombinant collagen I (ab6308; Abcam) was incubated at a concentration of
40 μg/ml with 200 ng active human PAD4 (ab196393; Abcam) in the presence or
absence of 1 mM or 0.05 mM BB-Cl-amidine for 24 h at 37 °C in a buffer of 20 mM
HEPES (pH 8.8), 10 mM CaCl2, 1 mM dithiothreitol (DTT), 1 mM ethylenedia-
minetetraacetic acid (EDTA), and 0.3 M NaCl. The concentrations of PAD4 and
collagen I were used to obtain the enzyme-to-substrate ratio of 1:10. Samples were
analyzed by LC-MS/MS for the presence of citrulline residues. For the coating
experiments, collagen density used was 10 µg/cm2. The mixture of collagen I and
PAD4 (and BB-Cl-amidine if needed) was prepared and immediately added into
wells (96-well, 24-well, or 6-well) and then incubated for 24 h at 37 °C in cell
culture incubator to prevent drying. Before plating the cells, the wells were dried in
a 37 °C incubator for 1–2 h and carefully washed with PBS three times.
Immunoﬂuorescence and H&E staining. Liver metastasis tissues, adjacent unaf-
fected liver tissues, and murine- or human-derived decellularized matrices were
embedded in optimal cutting temperature (OCT) compound (25608-930; Tissue-
Tek), ﬂash frozen and kept at −80 °C until cutting. Tissue sections were prepared
using the OTF 5000 cryostat (Bright instrument), and 12 μm slices were mounted
on Superfrost Plus microscope slides (4951PLUS4; Thermo Fisher). For immu-
noﬂuorescence, the sections were brought to RT, ﬁxed in ice-cold acetone (or 4%
paraformaldehyde or methanol depending on antibody), rehydrated, blocked with
20% goat serum, and incubated overnight with the primary antibodies. The fol-
lowing day, the slides were washed in PBS before being incubated with secondary
antibodies for 1 h at RT. The sections were washed and mounted using the Pro-
Long® Diamond Antifade Mountant with DAPI (P36962; Thermo Fisher).
Immunoﬂuorescence was visualized utilizing an inverted epiﬂuorescence micro-
scope (DM IRBE, Leica Microsystems) with a digital camera. All images were
acquired with either a ×10 or a ×20 objective. The excitation source was CoolED
pE-300 ultra. The images were processed using either ImageJ (National Institutes of
Health, Bethesda, MD) or Adobe Photoshop CS4 (Adobe Systems). For H&E
staining, slides were ﬁxed in ice-cold acetone for 10 min, then immersed in ﬁltered
Harris modiﬁed Hematoxylin solution (HHS16; Sigma) for 1 min, then rinsed with
tap water. The sections were immersed in 1% aqueous Eosin Y solution (HT110216;
Sigma) for 1–2 min and rinsed with tap water. The slides were dehydrated in
ascending alcohol solutions (50%, 70%, 80%, 95% × 2, and 100% × 2) and
cleared with xylene (214736; Sigma) two times for 5 min each. Finally, coverslips
were mounted onto a labeled glass slide with Permount Mounting Medium (SP15-
100; Thermo Fisher). For quantiﬁcation of liver metastatic areas, percent of meta-
static area in H&E-stained sections of comparable size was quantiﬁed using the
ImageJ software.
Protein extraction from cells and tissues. For protein extraction from cells, cell
pellets were lysed with RIPA lysis buffer (89900; Thermo Fisher), containing a
Complete Protease Inhibitor Cocktail (04693116001; Roche) or Protease/Phos-
phatase Inhibitor Cocktail (5872; CST) at a ratio of 5:1 or 1:100, respectively for 30
min at 4 °C on a rotary shaker. For protein extraction from intact or decellularized
tissues, 0.5 g of freshly dissected tissue was disrupted at 4 °C using an electric
Tissue-Tearor homogenizer, passed through a 70 μm cell strainer and spun down.
Cell pellets were resuspended in RIPA lysis buffer containing a protease inhibitor at
a ratio of 5:1 for 2 h at 4 °C on a rotary shaker. The extracts were brieﬂy sonicated
and then spun down at 12,000 × g at 4 °C for 10 min to remove insoluble material.
Protein concentration was determined using the BCA protein assay kit (23225;
Thermo Fisher). All protein suspensions were ﬂash frozen in liquid nitrogen and
kept at −20 °C until use.
Extracellular vesicles (EV). Cells were plated at high density (10 × 106) and
cultured for 48 h in DMEM supplemented with 0.1% EV-free media (depleted of
EVs by overnight centrifugation at 100,000 × g). Conditioned media was collected
and sequentially centrifuged at 2000 × g for 30 min, then 10,000 × g for 40 min,
then 100,000 × g for 18 h using OptimaTM XPN-80 Ultracentrifuge (Beckman
Coulter) and SW 32 Ti Rotor. At this point samples were removed for ELISA for
PAD4. Resulting pellets were washed with PBS and centrifuged at 100,000 × g for
1.5 h using OptimaTM MAX-XP Ultracentrifuge (Beckman Coulter) and TLA-55
rotor. All the centrifugations were performed at 4 °C. Resulting pellets were pro-
cessed for transmission electron microscopy analysis, immunoblotting, or nano-
particle tracking analysis. Protein concentration was normalized against number of
plated cells or measured using microBCA assay (23235; Thermo Fisher).
Uncropped immunoblotting images are presented in Supplementary Fig. 13.
GW4869. GW4869 was purchased from Sigma (D1692). Cancer cells were plated
at high density (10 × 106) and serum starved for 8 h. Media was changed for Opti-
MEM™ (31985070; Thermo Fisher) and 20 μM GW4869 was added to cells at time
points 0, 24, and 48 h. The conditioned medium was collected at 72 h and EVs were
isolated as described above. HT29 cells were unaffected in the WST-1 assay by
GW4869, but LoVo and HCT116 had reduced signal as a result, and EVs were not
collected after treatment for these cell lines (Supplementary Fig. 8C).
SDS-PAGE and gel silver staining. For the experiments shown in Supplementary
Fig. 1 and Supplementary Fig. 2, total protein (5 μg) obtained from intact tissue,
decellularized tissue, or decellularized biochemically enriched tissue, were mixed
with LDS sample buffer (NP0008, Life Technologies) at a ratio 4:1, and then loaded
on 1.0 mm 3–8% Tris-Acetate protein gradient gel (EA0375, Life Technologies).
Proteins were separated at 100 V for 2 h. Silver staining of gels was performed using
the SilverQuest staining kit (LC6070; Life Technologies) according to the manu-
facturer’s instructions. Images of the stained gels were acquired with the PhotoDoc-
It UVP Imaging System (Cole-Parmer, UK).
Immunoblot analysis. For immunoblotting, an equal amount of protein lysates
(8–60 μg, depending on the primary antibody used) were mixed with LDS sample
buffer at a ratio 4:1, and loaded on either 3–8% Tris-Acetate or 4–12% Bis-Tris
precast gels (NP0321; Life Technologies) for high and low molecular weight pro-
teins, respectively. Proteins were separated at 100 V for 1.5–3 h and transferred at
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30 V for 1–1.5 h 4 °C using the polyvinylidene ﬂuoride membrane (IPVH00010;
Millipore). Membranes were then blocked in either 5% bovine serum albumin
(A2153; Sigma) or 5% skimmed milk diluted in TBS supplemented with 0.05%
Tween-20 (P7949; Sigma) (TBST). Blots were incubated overnight at 4 °C with the
primary antibodies at dilutions ranging from 1:100 to 1:1000. The membranes were
washed three to ﬁve times for 10 min each in TBST, then horseradish peroxidase
conjugated secondary antibodies (all Santa-Cruz) were added at dilution 1:500 for
1 h at RT. The membranes were then washed three times for 10 min each in TBST.
Proteins were visualized with enhanced chemiluminescence by using the Amer-
sham ECL detection reagent (RPN2106; GE Healthcare) or the Odyssey® imaging
system (LI-COR) or an X-ray detector. Densitometric analysis of band intensity
was performed using the ImageJ software or the Image Studio™ Software (LI-COR).
Uncropped blots are provided in the Supplementary Information.
Citrullination immunoblot analysis. For determination of citrulline residues in
liver metastases tissues and adjacent unaffected liver tissues, a modiﬁed anti-
citrulline detection kit (17-347; Merck Millipore) was used according to manu-
facturer’s instructions. The assay principle is based on immunoblot technique using
the anti-citrulline antibody. To detect citrulline residues, the polyvinylidene
ﬂuoride membrane with transferred proteins was exposed overnight to 2,3-buta-
nedione monoxime and antipyrine in a strong acid solution (H2SO4) to form
ureido group adducts to citrulline residues. This ensures speciﬁc detection of
citrulline containing proteins disregarding any other amino acid sequences.
ELISA. For determination of citrulline residues in liver metastases tissues and
adjacent unaffected livers, an anti-citrulline human ELISA kit (MBS701429,
MyBioSource) was used according to manufacturer’s instructions. For determi-
nation of PAD4 levels in liver metastases tissues and adjacent unaffected livers, an
anti-PAD4 human ELISA kit (LS-F7962, LifeSpan BioSciences) was used according
to manufacturer’s instructions.
FACS and cell isolation. Dissected mouse livers were minced with a scalpel on ice
and incubated at 37 ˚C in RPMI-1640 media containing 0.05% collagenase/dispase
(11097113001; Roche) and 0.01% trypsin inhibitor (T7659; Sigma). Cell suspension
was ﬁltered through a 70 μm cell strainer into PBS and residual red blood cells
lysed using red cell lysis buffer (11814389001; Roche). Cell suspensions at a con-
centration of 1 × 107 cells/ml were the incubated for 45 min at 4 ˚C in the presence
of anti-CD11b PE-Cy7 (25-0112-82, eBioscience), anti-Gr1 PE (12-5931-82;
eBioscience), anti-CD45 PE (12-0451-82; eBioscience), anti-CXCR2-APC (149305;
Biolegend), and Mouse BD Fc Block (553141, BD Bioscience). FACS analysis was
performed using a FACSCalibur ﬂow cytometer (BD Biosciences) and analyzed
with FlowJo software version 7.2.5 (Tree Star, Ashland, OR).
Viability and proliferation assay. In total, 5 × 103 cells were seeded in 96-well
plates. Five to seven technical replicates per condition were used. After 24 h of
culture, media was replaced with fresh media containing 10% WST-1 (ab155902;
Abcam) and cells were left in the incubator for 1 h. Absorbance was read at 450 nm
using the plate reader. For experiments in Supplementary Fig. 9, we used a very
similar Cell Cytotoxicity Assay Kit (ab112118; Abcam). Here, after 24 h of culture,
media was replaced with fresh media containing 20% ab112118 and cells were left
in the incubator for 3 h. Absorbance was read at 570 and 605 nm using the plate
reader, and their ratio was used to evaluate viablility/proliferation.
Adhesion assays. In total, 5 × 104 GFP+ cells were seeded in triplicates in 6-well
plates pre-coated overnight (24 h) with collagen I, collagen I+ PAD4, or collagen I
+PAD4+BB-Cl-amidine (for details see "In vitro citrullination studies"). At 1, 2,
and 3 h time points, the plates were imaged using an inverted epiﬂuorescence
microscope at ×10 objective (DM IRBE, Leica Microsystems, at least ﬁve ﬁelds of
view per condition) and the number of adherent cells was manually counted.
Time-lapse microscopy. In total, 1 × 103 GFP+ cells were seeded in 96-well plates
pre-coated overnight (24 h) with collagen I, collagen I+ PAD4, or collagen I
+PAD4+BB-Cl-amidine (for details see "In vitro citrullination studies"). Wells
were washed with PBS three times to remove PAD4 or BB-Cl-amidine before cell
plating. Sixteen technical replicates were used per condition. After adherence, cells
were imaged for 20 h using the epiﬂourescent time-lapse microscope Nikon Ti-E at
×10 objective. Images were taken every 45 min. After the imaging session, indivi-
dual cells were tracked using the IMARIS software (Bitplane). Median cell track
distance and speed were analyzed.
mRNA extraction and real-time quantitative PCR. Total RNA was isolated from
FACS-sorted cells using RNeasy kit (74104; Qiagen) or TRIzol reagent (15596026,
Thermo Fisher), and then TURBO™ DNase kit was used to deplete DNA (AM2238;
Thermo Fisher). RNA concentration was measured using NanoDrop microvolume
spectrophotometer (Thermo Fisher). Samples were reverse transcribed using Tetro
cDNA synthesis kit (BIO-65042; Bioline) according to manufacturer’s instructions.
Resulting complementary DNA (cDNA) was analyzed using SYBR Green technology
in the Mx3000P instrument (Stratagene). Gene expression was compared by the way
of the ΔΔCt method after normalization to hypoxanthine guanine phosphoribosyl
transferase (HPRT) expression. The following real-time PCR primers were used:
human PAD4 forward (5′-TTGCAATCAACTGGAGCAGG-3′) and reverse (5′-AG
AGGGCTGAGGCCACCT-3′), mouse PAD4 forward (5′-TTACCACGGAGTTC
CACACC-3′) and reverse (5′-CTGCCAGCCATAGTTAAGC-3′), human HPRT
forward (5′-ATAGGACTCCAGATGTTTCC-3′) and reverse (5′-ATAAGCCA
GACTTTGTTGG-3′), mouse HPRT forward (5′-GCAGTACAGCCCCAAAATG
G-3′) and reverse (5′-AACAAAGTCTGGCCTGTATCCAA-3′).
For all other genes, pre-validated and optimized primers were ordered from
Sigma (KiCqStart®). For analysis of EMT gene expression in MC38 cells (Fig. 4f),
the commercially available gene array was used (PAHS-090Z; Sabiosciences) and
performed in accordance manufacturer’s instructions.
Conditioned media experiments. Cell conditioned media was concentrated using
centrifugal ﬁlter tubes (Merck). For Fig. 3e, original media samples were ﬁrst
concentrated, then split in two parts and loaded into two parallel gels. One gel was
blotted for PAD4, and another one was Coomassie stained (B7920; Sigma).
Statistical analysis. Data were analyzed and statistics were performed in Graph
Pad Prism version 5.03. Data are presented as mean ± s.e.m., or median ± inter-
quartile range, or box and whiskers and median, where whiskers indicate range.
Values with P < 0.05 were considered statistically signiﬁcant. FDR was used to
validate peptide and protein hits obtained during the quantitative LC-MS/MS
analysis. Two-way ANOVA was used to identify the difference between groups in
the quantitative proteomics analysis, subcutaneous tumor growth curves, and
viability/proliferation assays. For analysis of two groups with unpaired samples,
Mann–Whitney U test was used. For analysis of two groups with paired samples,
Wilcoxon signed rank test was used. In Fig. 2b, values in both groups were nor-
mally distributed (Kolmogorov–Smirnov test: P > 0.1), and therefore paired Stu-
dent’s t test was used. For analysis of three or more groups, Kruskal–Wallis test
with Dunn’s multiple comparison post-test was used. Statistical methods were not
used to predetermine necessary sample size, but sample sizes were based on review
of similar experiments in literature and previously published results such that
appropriate statistical tests could yield signiﬁcant results. Experiments were not
performed in a blinded fashion. The following symbols represent signiﬁcant dif-
ferences throughout the ﬁgures: *P= 0.01 to 0.05, **P= 0.001 to 0.01, ***P < 0.001.
Data availability
The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE partner repository with the dataset iden-
tiﬁer PXD010252 and 10.6019/PXD010252. Use the following link to access the
dataset: http://www.ebi.ac.uk/pride/archive/projects/PXD010252
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